ESMO 2024 – Scorpion joins Relay in the alpha club
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
ESMO 2024 – combos could be the way forward for CDK2
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
ESMO 2024 – Nuvalent looks beyond its late-line Alkove
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
ESMO 2024 – NiKang’s case for a better Welireg
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
World Lung 2024 – Lilly eyes a first-line KRAS triplet
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
An alpha turnaround for Relay
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
World Lung 2024 – Boehringer and Bayer battle over a lung cancer niche
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
World Lung 2024 – ArriVent looks for lung cancer white space
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.
